Tibsovo Approved for Acute Myeloid Leukemia

FRIDAY, July 20, 2018 -- Tibsovo (ivosidenib) tablets have been approved by the U.S. Food and Drug Administration to treat relapsed or refractory acute myeloid leukemia (AML) among people with a defective IDH1 gene. " The use of Tibsovo is associated...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news